These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34944102)

  • 1. Development of a 3-Dimensional Model to Study Right Heart Dysfunction in Pulmonary Arterial Hypertension: First Observations.
    Llucià-Valldeperas A; Smal R; Bekedam FT; Cé M; Pan X; Manz XD; Wijnker PJM; Vonk-Noordegraaf A; Bogaard HJ; Goumans MJ; Man FS
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
    Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
    Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a human iPSC-derived cardiomyocyte/fibroblast engineered heart tissue model.
    Cumberland MJ; Euchner J; Azad AJ; T N Vo N; Kirchhof P; Holmes AP; Denning C; Gehmlich K
    F1000Res; 2023; 12():1224. PubMed ID: 38298530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced pluripotent stem cell derived cardiac models: effects of Thymosin β4.
    Ziegler T; Hinkel R; Kupatt C
    Expert Opin Biol Ther; 2018 Jul; 18(sup1):111-120. PubMed ID: 30063852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afterload promotes maturation of human induced pluripotent stem cell derived cardiomyocytes in engineered heart tissues.
    Leonard A; Bertero A; Powers JD; Beussman KM; Bhandari S; Regnier M; Murry CE; Sniadecki NJ
    J Mol Cell Cardiol; 2018 May; 118():147-158. PubMed ID: 29604261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
    Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
    Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimentally-guided in silico design of engineered heart tissues to improve cardiac electrical function after myocardial infarction.
    Rosales RM; Mountris KA; Oliván-Viguera A; Pérez-Zabalza M; Cedillo-Servin G; Iglesias-García O; Hrynevich A; Castilho M; Malda J; Prósper F; Doblaré M; Mazo MM; Pueyo E
    Comput Biol Med; 2024 Mar; 171():108044. PubMed ID: 38335818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased length-dependent activation of human engineered heart tissue after chronic α
    Rupert C; López JE; Cortez-Toledo E; De la Cruz Cabrera O; Chesler NC; Simpson PC; Campbell SG; Baker AJ
    Am J Physiol Heart Circ Physiol; 2023 Mar; 324(3):H293-H304. PubMed ID: 36637971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrial-like Engineered Heart Tissue: An In Vitro Model of the Human Atrium.
    Lemme M; Ulmer BM; Lemoine MD; Zech ATL; Flenner F; Ravens U; Reichenspurner H; Rol-Garcia M; Smith G; Hansen A; Christ T; Eschenhagen T
    Stem Cell Reports; 2018 Dec; 11(6):1378-1390. PubMed ID: 30416051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An induced pluripotent stem cell model of hypoplastic left heart syndrome (HLHS) reveals multiple expression and functional differences in HLHS-derived cardiac myocytes.
    Jiang Y; Habibollah S; Tilgner K; Collin J; Barta T; Al-Aama JY; Tesarov L; Hussain R; Trafford AW; Kirkwood G; Sernagor E; Eleftheriou CG; Przyborski S; Stojković M; Lako M; Keavney B; Armstrong L
    Stem Cells Transl Med; 2014 Apr; 3(4):416-23. PubMed ID: 24591732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene correction and overexpression of TNNI3 improve impaired relaxation in engineered heart tissue model of pediatric restrictive cardiomyopathy.
    Hasegawa M; Miki K; Kawamura T; Takei Sasozaki I; Higashiyama Y; Tsuchida M; Kashino K; Taira M; Ito E; Takeda M; Ishida H; Higo S; Sakata Y; Miyagawa S
    Dev Growth Differ; 2024 Feb; 66(2):119-132. PubMed ID: 38193576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
    Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
    J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptome analysis of non human primate-induced pluripotent stem cell-derived cardiomyocytes in 2D monolayer culture vs. 3D engineered heart tissue.
    Yang H; Shao N; Holmström A; Zhao X; Chour T; Chen H; Itzhaki I; Wu H; Ameen M; Cunningham NJ; Tu C; Zhao MT; Tarantal AF; Abilez OJ; Wu JC
    Cardiovasc Res; 2021 Jul; 117(9):2125-2136. PubMed ID: 33002105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation.
    Hirt MN; Boeddinghaus J; Mitchell A; Schaaf S; Börnchen C; Müller C; Schulz H; Hubner N; Stenzig J; Stoehr A; Neuber C; Eder A; Luther PK; Hansen A; Eschenhagen T
    J Mol Cell Cardiol; 2014 Sep; 74():151-61. PubMed ID: 24852842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel measures of left ventricular electromechanical discoordination predict clinical outcomes in children with pulmonary arterial hypertension.
    Frank BS; Schäfer M; Douwes JM; Ivy DD; Abman SH; Davidson JA; Burzlaff S; Mitchell MB; Morgan GJ; Browne LP; Barker AJ; Truong U; von Alvensleben JC
    Am J Physiol Heart Circ Physiol; 2020 Feb; 318(2):H401-H412. PubMed ID: 31858817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human induced pluripotent stem cell-derived cardiomyocytes reveal abnormal TGFβ signaling in type 2 diabetes mellitus.
    Tang L; Wang H; Dai B; Wang X; Zhou D; Shen J; Guo F; Wang J; Zhou J; Wang H; Wu Q; Yao H; Gong T; Su J; Meng ZX; Niu T; Zhang L; Liang P
    J Mol Cell Cardiol; 2020 May; 142():53-64. PubMed ID: 32251671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of KCNJ2 enhances maturation of human-induced pluripotent stem cell-derived cardiomyocytes.
    Zhou J; Cui B; Wang X; Wang H; Zheng J; Guo F; Sun Y; Fan H; Shen J; Su J; Wang J; Zhao H; Tang Y; Gong T; Sun N; Liang P
    Stem Cell Res Ther; 2023 Apr; 14(1):92. PubMed ID: 37061738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Speckle-Tracking Strain Analysis for Mapping Spatiotemporal Contractility of Induced Pluripotent Stem Cell (iPSC)-Derived Cardiomyocytes.
    Izadifar M; Berecz T; Li B; Tang JKKY; Foldes G; Apati A; Nagy A
    Curr Protoc; 2023 Sep; 3(9):e889. PubMed ID: 37747346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced structural maturation of human induced pluripotent stem cell-derived cardiomyocytes under a controlled microenvironment in a microfluidic system.
    Kolanowski TJ; Busek M; Schubert M; Dmitrieva A; Binnewerg B; Pöche J; Fisher K; Schmieder F; Grünzner S; Hansen S; Richter A; El-Armouche A; Sonntag F; Guan K
    Acta Biomater; 2020 Jan; 102():273-286. PubMed ID: 31778832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of somatic cell sources in the maturation degree of human induced pluripotent stem cell-derived cardiomyocytes.
    Pianezzi E; Altomare C; Bolis S; Balbi C; Torre T; Rinaldi A; Camici GG; Barile L; Vassalli G
    Biochim Biophys Acta Mol Cell Res; 2020 Mar; 1867(3):118538. PubMed ID: 31472168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.